Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models

Andreani, Tatiana; Miziara, Leonardo; Lorenzón, Esteban Nicolás; Souza, Ana Luiza Ribeiro de; Kiill, Charlene P.; Fangueiro, Joana F.; García, María L.; Gremião, Palmira D.; Silva, Amélia M.; Souto, Eliana B.

doi:10.1016/j.ejpb.2015.03.027

Cited by 91 publications

(46 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an index of the bioadhesive potential of the formulation, the interaction between the nanoemulsion and mucin was assessed (Mazzarino et al, 2012). A dispersion of porcine stomach mucin at 250 mg/mL was prepared in phosphate buffer (Sigma, St. Louis, MO, 10 mM, pH 7.4) and incubated with the nanoemulsion (1%, v/v) at 37 C for 30 min under stirring (100 rpm, n ¼ 3 for each treatment) (Mazzarino et al, 2012;Andreani et al, 2015). As controls, the mucin dispersion and the nanoemulsion were incubated individually with PBS.…”

Section: Evaluation Of the Bioadhesive Potential Of The Formulationmentioning

confidence: 99%

Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer

et al. 2018

View full text Add to dashboard Cite

Considering that breast cancer usually begins in the lining of the ducts, local drug administration into the ducts could target cancers and pre-tumor lesions locally while reducing systemic adverse effects. In this study, a cationic bioadhesive nanoemulsion was developed for intraductal administration of C6 ceramide, a sphingolipid that mediates apoptotic and non-apoptotic cell death. Bioadhesive properties were obtained by surface modification with chitosan. The optimized nanoemulsion displayed size of 46.3 nm and positive charge, properties that were not affected by ceramide encapsulation (0.4%, w/w). C6 ceramide concentration necessary to reduce MCF-7 cells viability to 50% (EC) decreased by 4.5-fold with its nanoencapsulation compared to its solution; a further decrease (2.6-fold) was observed when tributyrin (a pro-drug of butyric acid) was part of the oil phase of the nanocarrier, a phenomenon attributed to synergism. The unloaded nanocarrier was considered safe, as indicated by a score <0.1 in HET-CAM models, by the high survival rates of Galleria mellonella larvae exposed to concentrations ≤500 mg/mL, and absence of histological changes when intraductally administered in rats. Intraductal administration of the nanoemulsion prolonged drug localization for more than 120 h in the mammary tissue compared to its solution. These results support the advantage of the optimized nanoemulsion to enable mammary tissue localization of C6 ceramide.

show abstract

Section: Evaluation Of the Bioadhesive Potential Of The Formulationmentioning

confidence: 99%

Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The exceptional, unique, and singular characteristics of nanopharmaceuticals are associated with their size, matrix composition, and surface properties [4,5,11,[40][41][42][43]. As such, the current legislation must suffer a shift to attend the needs of these new types of pharmaceuticals as these are not approachable with the current regulation applied to health products.…”

Section: Good Manufacturing Practices Applied To Nanopharmaceuticalsmentioning

confidence: 99%

Nanopharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU

et al. 2020

Self Cite

View full text Add to dashboard Cite

The latest advances in pharmaceutical technology are leading to the development of cutting edged approaches to produce what is now known as the “Holy Grail” of medicine—nanopharmaceutics. Over the latest decade, the pharmaceutical industry has made important contributions to the scale up of these new products. To ensure their quality, efficacy, and safety for human use, clinical trials are mandatory. Yet, regulation regarding nanopharmaceuticals is still limited with a set of guidelines being recently released with respect to compliance with quality and safety. For the coming years, updates on regulatory issues about nanopharmaceuticals and their use in clinical settings are expected. The use of nanopharmaceuticals in clinical trials depends on the approval of the production methods and assurance of the quality of the final product by implementation and verification of the good manufacturing practices (GMP). This review addresses the available legislation on nanopharmaceuticals within the European Union (EU), the GMP that should be followed for their production, and the current challenges encountered in clinical trials of these new formulations. The singular properties of nanopharmaceuticals over their bulk counterparts are associated with their size, matrix composition, and surface properties. To understand their relevance, four main clinical trial guidelines, namely, for intravenous iron-based nanopharmaceuticals, liposomal-based nanopharmaceuticals, block copolymer micelle-based nanopharmaceuticals, and related to surface coating requirements, are described here.

show abstract

“…From the great variety of applications, such as those in mining, water treatment, paper industry, biotechnology, food and cosmetic industries and agriculture, soluble chitosans and their derivatives have been increasingly applied in biology and medicine [87][88][89][90][91][92][93][94][95][96][97][98][99]. Sustaining this worldwide application is the fact that chitosan and derivatives seem to be readily absorbed by enterocytes, have low toxicity to eukaryotes, immune system stimulation and hypocholesterolemic and anti-tumor activities [38].…”

Section: Water-soluble Chitosanmentioning

confidence: 99%

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

et al. 2019

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.

show abstract

Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models

Cited by 91 publications

References 84 publications

Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer

Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer

Nanopharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

Contact Info

Product

Resources

About